San Jose, California, August 4, 2016. DynoSense Corp. announcing today that it has received CE Mark approval for the commercial sale of its Remote Health Monitoring System. This will allow the company to launch the product in European Union countries as well as United Kingdom in collaboration with its partners.

This innovative and worldwide patented technology will mark a new paradigm in how patients are remotely monitored for physiological changes. Vital measurements will include [I] Electrocardigram (EKG or ECG) for analysis of heart parameters such as rate, and rhythm, [ii] Photoplethysmography for extracting Blood Oxygen (SPO2), [iii] Pulmonary Plethysmography, for extracting respiration rate, [iv] Oral Body Temperature, and in addition Breath Gas analysis for Ethanol.

“This is a major milestone both for our company and for our partners” stated Saeed Azimi, CEO of DynoSense Corp., “Actionable remote health monitoring is fundamental to shift from a reactive to preventive healthcare paradigm addressing major markets of chronic care and elderly healthcare management. DynoSense is now working with diverse companies to adopt this technology within respective market regions”.

About CE Certification:

CE marking is the medical device manufacturer’s claim that a product meets the essential requirements of all relevant European Medical Device Directives and is a legal requirement to place a device on the market in the European Union.

About DynoSense Corp.

Founded in 2013, DynoSense Corp. is a digital health innovator based in San Jose, CA. The company’s vision is to be the dominant force behind the digital healthcare revolution. Its mission is: “to provide advanced health assessment and health management solutions.”

For more information on DynoSense and its products, please visit: www.dynosense.com

Media Contact:

DynoSense Corp.
Attn: Media Relations
100 Century Center Court, Suite 650
San Jose, CA 95112
650.397.6103
info@dynosense.com